Nothing Special   »   [go: up one dir, main page]

EA201991336A1 - Способы лечения рака с помощью антител к pd-1 - Google Patents

Способы лечения рака с помощью антител к pd-1

Info

Publication number
EA201991336A1
EA201991336A1 EA201991336A EA201991336A EA201991336A1 EA 201991336 A1 EA201991336 A1 EA 201991336A1 EA 201991336 A EA201991336 A EA 201991336A EA 201991336 A EA201991336 A EA 201991336A EA 201991336 A1 EA201991336 A1 EA 201991336A1
Authority
EA
Eurasian Patent Office
Prior art keywords
antibodies
methods
treating cancer
cancer
patients
Prior art date
Application number
EA201991336A
Other languages
English (en)
Inventor
Дэвид Дженкинс
Хэйли Лэйкен
Элли Им
Аллен Диаз
Шэрон Лу
Original Assignee
Тесаро, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Тесаро, Инк. filed Critical Тесаро, Инк.
Priority claimed from PCT/US2018/013029 external-priority patent/WO2018129559A1/en
Publication of EA201991336A1 publication Critical patent/EA201991336A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

В настоящем изобретении предусмотрены способы введения определенных связывающих PD-1 средств пациентам, имеющим рак. Также подробно представлены схемы введения доз для композиций, содержащих связывающее PD-1 средство.
EA201991336A 2017-09-09 2018-01-09 Способы лечения рака с помощью антител к pd-1 EA201991336A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762556386P 2017-09-09 2017-09-09
PCT/US2018/013029 WO2018129559A1 (en) 2017-01-09 2018-01-09 Methods of treating cancer with anti-pd-1 antibodies

Publications (1)

Publication Number Publication Date
EA201991336A1 true EA201991336A1 (ru) 2020-01-09

Family

ID=69374484

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201991336A EA201991336A1 (ru) 2017-09-09 2018-01-09 Способы лечения рака с помощью антител к pd-1

Country Status (1)

Country Link
EA (1) EA201991336A1 (ru)

Similar Documents

Publication Publication Date Title
MX2019008208A (es) Métodos para tratar el cáncer con anticuerpos anti-tim-3.
MX2019008207A (es) Métodos para tratar el cáncer con anticuerpos anti-pd-1.
CY1124791T1 (el) Μορια δεσμευσης ειδικα για cd73 και χρησεις αυτων
CY1122984T1 (el) Καρβαμιδικες ενωσεις και μεθοδοι παρασκευης και χρησης τους
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
EA201790674A1 (ru) Индуцирующий цитотоксичность терапевтический агент
EA201692285A1 (ru) Ингибиторы ezh2 для лечения лимфомы
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
EA201891983A1 (ru) Комбинированная терапия антителами к cd73
MX2019001517A (es) Complejos de nanopartículas de albúmina modificada con anticuerpos para el tratamiento del cáncer.
EA201692530A1 (ru) Цитотоксические пептиды и их конъюгаты
MX2019008028A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor en folato 1 (folr1).
MX2018011054A (es) Metodos para tratar cancer de mama er+, her2-, hrg+ usando terapias de combinacion que comprenden un anticuerpo anti-erbb3.
GEP20217271B (en) Combination therapy for the treatment of cancer
MX2021009222A (es) Regimenes de dosificacion de inmunoconjugado anti-receptor 1 de folato (folr1).
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201791203A1 (ru) ЛЕКАРСТВЕННЫЙ КОНЪЮГАТ АНТИТЕЛА ПРОТИВ с-МЕТ
MY186711A (en) Igf-1r antibody-drug-conjugate and its use for the treatment of cancer
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
EA201791227A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
MX2019015527A (es) Conjugados y composiciones de texafirina-pt (iv) para su uso para superar la resistencia del platino.
EA202090741A1 (ru) Конъюгаты антитела к тканевому фактору и лекарственного средства и их применение в лечении рака
BR112017011538A2 (pt) combinação de anticorpos anti-cs1 e anti-pd1 para tratar câncer (mieloma)
MX2019003755A (es) Regimen de dosificacion de avelumab para el tratamiento de cancer.